Mirabegron + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intraocular Pressure

Conditions

Intraocular Pressure

Trial Timeline

Nov 1, 2010 → Feb 1, 2011

NCT ID

NCT01284309

About Mirabegron + Placebo

Mirabegron + Placebo is a phase 1 stage product being developed by Astellas Pharma for Intraocular Pressure. The current trial status is completed. This product is registered under clinical trial identifier NCT01284309. Target conditions include Intraocular Pressure.

What happened to similar drugs?

0 of 3 similar drugs in Intraocular Pressure were approved

Approved (0) Terminated (1) Active (2)

🔄OMS302 + PlaceboOmeros CorporationPhase 3

❌Part 1 OMS302 + Part 2 OMS302 + Part 2 PlaceboOmeros CorporationPhase 3

🔄OMS302 + PlaceboOmeros CorporationPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04641975	Phase 3	Terminated	Mar 15, 2021	Jul 24, 2023	Overactive Bladder (OAB)
NCT02787083	Phase 3	Terminated	Aug 1, 2016	Jul 5, 2019	Cystitis, Interstitial
NCT02216214	Approved	Completed	Oct 7, 2014	Jan 2, 2018	Overactive Bladder (OAB)
NCT02086188	Approved	Completed	May 1, 2014	Jun 1, 2019	Multiple Sclerosis
NCT02092181	Approved	Completed	Mar 1, 2014	Jul 1, 2018	Parkinsons Disease
NCT01284309	Phase 1	Completed	Nov 1, 2010	Feb 1, 2011	Intraocular Pressure
NCT00912964	Phase 3	Completed	Apr 28, 2009	Apr 27, 2010	Urinary Bladder, Overactive
NCT00662909	Phase 3	Completed	Mar 28, 2008	Apr 22, 2009	Urinary Bladder, Overactive
NCT00410514	Phase 2	Completed	Dec 1, 2006	Aug 1, 2008	Lower Urinary Tract Symptoms

Competing Products

6 competing products in Intraocular Pressure

See all competitors

Product	Company	Stage	Hype Score
AZD4017 + Placebo + AZD4017 + Placebo	AstraZeneca	Phase 2	35
ipilimumab + Tyrosinase/gp100/MART-1 Peptides	Bristol Myers Squibb	Phase 2	35
OMS302 + Placebo	Omeros Corporation	Phase 3	34
Part 1 OMS302 + Part 2 OMS302 + Part 2 Placebo	Omeros Corporation	Phase 3	26
OMS302 + Placebo	Omeros Corporation	Phase 3	34
cisplatin + sunitinib malate + tamoxifen citrate	Pacific Biosciences	Phase 2	21